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Abstract
The effects of double release of insulin-like growth factor I (IGF-I) and growth factor b1 (TGF–b1) from
nanoparticles on the growth of bone marrow mesenchymal stem cells and their differentiation into
cartilage cells were studied on PLGA scaffolds. The release was achieved by using nanoparticles of poly
(lactic acid-co-glycolic acid) (PLGA) and poly(N-isopropylacrylamide) (PNIPAM) carrying IGF-I and
TGF–b1, respectively. On tissue culture polystyrene (TCPS), TGF-b1 released from PNIPAM nanoparticles
was found to have a significant effect on proliferation, while IGF-I encouraged differentiation, as shown by
collagen type II deposition. The study was then conducted onmacroporous (pore size 200–400mm) PLGA
scaffolds. It was observed that the combination of IGF-I and TGF-b1 yielded better results in terms of col-
lagen type II and aggrecan expression than GF-free and single GF-containing applications. It thus appears
that gradual release of a combination of growth factors from nanoparticles could make a significant
contribution to the quality of the engineered cartilage tissue. Copyright © 2011 John Wiley & Sons, Ltd.
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1. Introduction
Articular cartilage can resist a significant amount of mechan-
ical stress; however, it has a very limited self-repair capabil-
ity upon suffering a trauma (Hunziker, 1999). Studies on
cartilage degeneration have shown that aggrecan fragments
are generated by aggrecanase action in the synovial fluids of
healthy individuals and of patients with osteoarthritis,
rheumatoid arthritis and acute knee injuries (Lohmander
et al., 1993). Degraded aggrecan molecules can no longer
protect the collagen fibres, which in turn undergo
proteolytic degradation, and the result is articular
cartilage degeneration (Sztrolovics et al., 1997).
Cartilage treatment by transplantation of autogenous
or allogenous chondrocytes, or through the use of
mesenchymal stem cells (MSCs), has several advantages
over solid tissue transplantation or local debridement
procedures. However, allogenous chondrocytes carry an
inherent risk of an immune reaction, while autogenous
chondrocytes lack a suitable donor site, and the need for
large samples limit chondrocyte transfer from either
(Worster et al., 2001).
Cartilage tissue engineering can offer a solution to this
problem, but the selection of appropriate cell type, the
fabrication of biocompatible and mechanically stable scaf-
folds and the amount and timing of growth factor delivery
are highly crucial to obtaining satisfactory results. Worster
et al. (2001) demonstrated that MSCs cultured with IGF-I
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were significantly more chondrogenic than when pre-
treated with TGF-b1, highlighting the importance of the
role of growth factor supplementation.
As reported in the literature, there are two growth fac-
tors that play a major role in chondrocyte proliferation
and differentiation. These are insulin-like growth factor I
(IGF-I) and transforming growth factor b1 (TGF-b1)
(Croucher and Russell, 1999). IGF-I is known to drive
DNA synthesis in a number of cell types, including chon-
drocytes, and stimulates the chondrocytes in the serum
(Kim et al., 2000; Elisseeff et al., 2001). In addition, it
increases the synthesis of proteoglycan and collagen type
II and thus assists cartilage formation (Loeser et al., 2003;
Darling and Athanasiou, 2005). TGF-b1, on the other
hand, is reported to enhance extracellular matrix (ECM)
fabrication and stimulate cell proliferation (Guerne
et al., 1994; Blunk et al., 2002). Thus, these two growth
factors have significant and complementary activities in
cartilage formation.
Since the times of bioavailability of these growth fac-
tors are not the same, scientists started testing combina-
tions of growth factors released at different times to
mimic this. Jaklenec et al. (2008) showed sequential re-
lease of bioactive IGF-I (as a mitogenic factor enhancing
growth in adult cells, as well as aiding in embryonic
growth and differentiation) and TGF-b1 (which induces
chondrogenesis) from PLGA microsphere-based scaffolds.
They reported that the ability of these scaffolds to release
IGF-I and TGF-b1 sequentially was very useful in cartilage
tissue engineering.
In other studies, IGF and TGF-b1 were released from
poly(lactic acid-co-glycolic acid) (PLGA) and poly(N-
isopropylacrylamide) (PNIPAM) nanoparticles, respec-
tively, to enhance cartilage regeneration by mimicking
the natural process of healing. Examples include the
study of Lim et al. (2010), in which dual growth factor
release from alginate (containing BMP-7) and polyion
complex nanoparticles (containing TGF-b2) improved
chondrogenesis. Similarly, the simultaneous delivery
of dexamethasone and TGF-b3 from PLGA nanoparti-
cles enhanced chondrogenesis significantly, both
in vitro and in vivo (Park et al., 2009).
PNIPAM has been one of the most frequently studied
polymers in biomedical applications. It shrinks after the
lower critical solution temperature (LCST) of 32.5 C
and therefore is a good material to use as a responsive
drug carrier. Since it expels its liquid contents at a temper-
ature near that of the human body, PNIPAM has been
investigated by many researchers for controlled drug
delivery applications (Chung et al., 1999), in enzyme
immobilization (Hamerska-Dudra et al., 2007), gene
delivery (Twaites et al., 2005), drug delivery (Verestiuc
et al., 2006), cell culture (Ozturk et al., 2009) and cell
sheet engineering (Jeong et al., 2002; Cooperstein and
Canavan, 2009). PLGA, on the other hand, is a synthetic
polymer that is approved by the US Food and Drug
Administration (FDA) for various biomedical applications
and therefore is the most widely used polymer in bioma-
terials and tissue engineering (Kim and Mooney, 1998).
Chondroitin sulphate is an essential component of carti-
lage tissue, so its presence in the scaffold might lead to
differentiation (Hardingham, 1998). Alginic acid is a lin-
ear block copolymer polysaccharide consisting of b-D-
mannuronic acid and a-L-glucuronic acid residues joined
by 1,4-glycosidic linkages. Dilute aqueous solutions of
alginates form firm gels on addition of di- and trivalent
metal ions by a cooperative process involving consecutive
glucuronic residues in the a-L-glucuronic acid blocks of
the alginate chain (Madan et al., 2009).
In this study, the effects of GF released from nanoparti-
cles on cells seeded into 24-well plate tissue culture poly-
styrene (TCPS) and on three-dimensional (3D) PLGA scaf-
folds were determined. The nanoparticles were loaded
into the scaffolds and entrapped in these locations by a
coat of alginic acid, which was chosen because of its bio-
compatibility and biodegradability. For that purpose,
PLGA scaffolds were first loaded with chondroitin sul-
phate to encourage the differentiation of cells by mimick-
ing the cartilage tissue. After loading of the nanoparticles,
cells were seeded and finally alginic acid was added and
crosslinked to prevent the escape of the nanoparticles
from the construct. Since alginic acid can be easily cross-
linked in an aqueous Ca2+ solution, thus avoiding the
use of organic solvents and any other chemical treatments
that may harm and reduce bioactivity of the growth fac-
tors (Basmanav et al., 2008). Entrapment of both the cells
and the nanoparticles under a thin coat of alginic acid is
important, since this construct is planned for use in
in vivo applications. The effects of these growth factors
were studied by measuring proliferation, differentiation
and immunohistochemistry.
2. Materials and methods
2.1. Isolation and culture of MSCs from bone
marrow
Male Sprague–Dawley rats, 6weeks old and weighing
150–170 g, were used as a source for bone marrow
stromal cells (Torun Kose et al., 2003). Briefly, following
euthanasia by diethyl ether inhalation, femurs were asep-
tically excised and the soft tissue cleaned off, then washed
in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 1000 units/ml penicillin and 1000 units/ml strepto-
mycin. The marrow was flushed out with 5ml primary
medium [DMEM containing 20% fetal bovine serum
(FBS), 100 units/ml penicillin and 100 units/ml strepto-
mycin], then centrifuged at 400 g for 10min. The result-
ing cell pellets were resuspended in 12ml primary
medium and plated in T-75 flasks (cells from two femurs
per flask) and incubated in an incubator under 5% CO2
at 37 C. The haematopoietic stem cells and other cells
were excluded from the flasks by washing with
phosphate-buffered saline (PBS, 500mM, pH 7.4; Invitro-
gen, Darmstadt, Germany). DMEM–high glucose with
10% fetal bovine serum (FBS; Invitrogen), 100 U/ml
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penicillin–streptomycin (Biochrom, Berlin, Germany) was
added and the cells were incubated in a CO2 incubator at
37 C under 5% CO2 and the medium was refreshed every
other day. When the cells reached confluence they were
detached with trypsin (0.25%)–EDTA (Invitrogen) treat-
ment for 5min at 37 C. Total cell number was determined
using a C-reader Automatic Cell Counter (INCYTO,
Chungnam, Korea) by using C-Reader chips and cell viabil-
ity stain solutions. The cells were determined using a flow
cytometer (BD FACSCalibur, USA) to be mesenchymal
stem cells (MSCs; data not shown).
2.2. Preparation of growth factor-loaded PLGA
and PNIPAM nanoparticles
Bovine serum albumin (BSA) was used as a model protein
in place of the growth factors during investigation of the
release kinetics from nanoparticles. In order to encapsu-
late IGF-I (or the model compound BSA) in PLGA
(50:50), 10% w/v nanocapsules, water-in-oil-in-water
(w/o/w) system developed by Yilgor et al (2009) was
used. Briefly, an aqueous solution of the IGF-I (100 ml,
0.1mg/ml) was dispensed in a dichloromethane solution
of PLGA (600 ml, 10 %w/v; Boehringer, Ingelheim,
Germany) by probe sonication for 15 s at 50W. This w1/o
emulsion (700ml) was added into an aqueous solution of
PVA (4% w/v, 2ml) and sonicated (50W, 15 s) to form
the (w1/o/w2) emulsion. This double emulsion was then
added into more PVA (0.3% w/v, 50ml) and the medium
was vigorously stirred overnight. The nanocapsules
were collected by centrifugation (15 000 g, 10min),
washed twice with Tris–HCl, pH 7.4, resuspended in
distilled water and lyophilized after freezing at 80 C.
PNIPAM polymers were prepared via free radical poly-
merization. N,N-methylene bisacrylamide (MBA; 0.44%
w/v) and N-isopropylacrylamide monomer (1g, 10% w/v)
were dissolved in distilled water (10ml). The polymer-
ization was carried out at 65 C for 16 h in the oven by us-
ing ammonium persulphate (APS; 0.3ml from 5% APS
stock solution) as the initiator and N,N,N,N-tetramethyl
ethylenediamine (TEMED; 0.3ml from 10% TEMED stock
solution) as the accelerator under a nitrogen atmosphere.
Before polymerization, N2 gas was bubbled through the
solution for a few minutes and then the system was
sealed. After the completion of the reaction, the polymer
was washed several times with ethanol and distilled
water.
N,N-Methylene bisacrylamide (MBA; Merck, Darmstadt,
Germany)-crosslinked PNIPAM (Sigma-Aldrich, Taufkirchen,
Germany) nanoparticles carrying TGF-b1 (or the model
compound BSA) were prepared by nanoprecipi-
tation (Bayyurt, 2009). TGF-b1 was loaded into these
nanoparticles by equilibrium partitioning. PNIPAM nano-
particles (10mg) were added to an aqueous solution of
TGF-b1 (0.2ml, 5mg/ml TGF-b1 in 4mM HCl and 0.1%
BSA). The suspension was cooled to 4 C to allow the PNI-
PAM particles to absorb and was maintained in this state
for 24h. The PNIPAM container was then brought to
37 C to get PNIPAM above its LCST and to entrap TGF-b
1. The particles were centrifuged at 13 500 rpm for 20min
and the nanoparticle pellet was dried at 37 C overnight.
2.3. Encapsulation efficiency
The encapsulation efficiency of PLGA nanocapsules was
determined by dissolving the particles with dichloro-
methane, followed by repeated extraction with water.
The protein content was then quantified using the stan-
dard Bradford assay.
Encapsulation efficiency in PNIPAM nanoparticles was
calculated from the difference between the input and
the unabsorbed protein in the loading medium, using
the Bradford assay (Bayyurt, 2009).
2.4. Nanoparticle shape and size determination
An aqueous suspension of PLGA nanoparticles (50 ml) was
added onto double sided adhesive carbon tapes. Scanning
electron microscopy (SEM) stubs and the morphology of
the nanoparticles were investigated by SEM (QUANTA
400 F Field Emission SEM, The Netherlands) after sput-
ter-coating with gold; high vacuum (HV), 20.00 kV; mag-
nification, 50 000; working distance (WD), 9.3 mm).
The size of the particles was determined by using Image
J (NIH, USA) and SEM micrographs. Size distributions
were determined using a Malvern Nano ZS90 (UK) system
(Yilgor et al., 2010).
The physical appearance of the PNIPAM particles
(roundness, smoothness and formation of aggregates)
was studied by SEM. Samples were prepared by spreading
concentrated nanoparticle dispersions over SEM stubs.
NPs were coated with gold under vacuum and were ob-
served in a Quanta 400 F field emission SEM (FE–SEM).
The size and distribution of particles were determined us-
ing the image analysis software Image J (NIH, USA) and
SEM micrographs.
2.5. GF release studies
In an earlier study (Yilgor et al., 2009), BSA and BMPs
were released from PLGA nanocapsules and the encapsu-
lation efficiency and release kinetics were found to be sim-
ilar, so in the present study the nanocapsules were
expected to behave as before, presenting a similar release
kinetics for the IGF-I and the BSA; therefore, in the cur-
rent study, only the release kinetics of BSA were studied
because of their convenience.
PLGA nanocapsules (5mg) were placed in PBS (1ml,
pH 7.4) in Eppendorf tubes and incubated at 37 C. At var-
ious time points (3 h and 1, 2, 4, 6, 8, 10, 15 and 21 days)
the samples were centrifuged, and the released protein in
the supernatant was determined using the Bradford assay,
as described by the manufacturer. Briefly, 150 ml of the
sample was put into a 96-well plate and 150 ml Bradford
reagent was added to the wells. After 10min at room
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temperature, the absorbance at 595 nm was determined
using a plate reader (Molecular Devices, USA). The absor-
bance was correlated with the protein concentration, us-
ing a calibration curve. The nanocapsules were then
resuspended in 1ml fresh PBS solution and incubation
was continued.
The same method (Bradford assay) was used to detect
BSA content and the release kinetics of the PNIPAM nano-
particles. After obtaining pellets containing BSA-loaded
PNIPAM nanoparticles, as described above, supernatant
was collected to determine the unloaded BSA amount,
which was used to calculate the encapsulation efficiency
and the loading of the PNIPAM nanoparticles. The BSA
release of PNIPAM nanoparticles was investigated by plac-
ing BSA-loaded PNIPAM nanoparticles (5mg) in PBS
(1ml, pH 7.4) in Eppendorf tubes and incubating at
37 C. The supernatants were collected at determined
time points and the protein concentrations were deter-
mined by comparing the absorbance of the solutions with
a standard curve, as described above.
2.6. In vitro studies on TCPS with BMSCs
Cartilage differentiation medium (1ml/well, DMEM-high
glucose; Sigma-Aldrich, Taufkirchen, Germany) with 100
unit/ml penicillin-streptomycin, 6.25mg/ml insulin,
6.25mg/ml transferrin, 6.25mg/ml selenic acid (ITS;
Invitrogen, Darmstadt, Germany), 5.33mg/ml linoleic acid,
40mg/ml proline,100mg sodium pyruvate, 1.25mg/ml BSA
(Sigma-Aldrich), 50mg/ml L-ascorbic acid and 100nM
dexamethasone (AppliChem, Darmstadt, Germany) were
put into 24-well plates containing BMSC (25 000 cells/
well). The effect of the growth factors on the cells was stud-
ied, using their different combinations (Table 1).
In order to direct the BMSC stem cells to cartilage dif-
ferentiation, samples with cells only (OC) were incubated
in cartilage differentiation medium as controls. As blanks
of IGF-I-loaded PLGA nanocapsules (IP) and TGF-b1-
loaded PNIPAM nanospheres (TN), growth factor-free
(empty) PLGA nanocapsules (EP) and empty PNIPAM
nanospheres (EN) were used. A control without nanopar-
ticles and growth factors (OC) was also tested, along with
the nanoparticle carrying samples. Each study was carried
out in triplicate on days 1, 7 and 14. Final concentrations
of 10 ng/ml TGF-b1 and 100 ng/ml IGF-I in the nanoparti-
cles were achieved in the media by using appropiate
amounts of nanoparticles.
2.7. Determination of cell numbers
At predetermined times, the MTS test (CellTiter 96W
Aqueous One Solution Cell Proliferation Assay, Promega,
WI, USA) was used to determine the number of cells
(Torun Kose et al., 2003). MTS/PMS reagent (100 ml)
was added to each well of the 24-well plate and incubated
for 140min at 37 C in a CO2 incubator. Absorbance was
determined at 490 nm, using an Elisa Plate Reader
(Bio-Tek, ELx400, USA). All experiments were repeated
three times. An absorbance vs cell number calibration
curve was used to calculate the cell numbers.
2.8. Determination of collagen deposition using
hydroxyproline sssay
Determination of collagen deposition by the BMSCs was
carried out by determining the amount of hydroxyproline,
according to Pratta et al. (2003). The cell culture medium
in which the samples incubated was discarded, 50 ml 12M
HCl was added and then the samples were incubated for
18 h at 100 C. The hydrolysate was further incubated
overnight to dry the samples in a dessicator with NaOH
pellets. The residue was dissolved in 150 ml water and
dried in a fume hood. Water (60 ml) was then added to
each sample, followed by 20 ml assay buffer (1-propanol:
water:pH 6 buffer; 3:2:10 ratio). Chloramine T reagent
(40 ml, 50mM) was added and samples were shaken for
15min at room temperature. After the addition of DMBA
reagent (2 g dimethylamino benzaldehyde, 1.25ml 1-
propanol, 2.75ml perchloric acid), the samples were
incubated for 20min at 70 C, then allowed to cool. Absor-
bances were measured at 570 nm, using a Thermo
LabSystems Multiscan Spectrum microplate reader
(Model 1500, USA). The data were converted to the
amount of hydroxyproline (g), using a hydroxyproline
standard curve. The DNA content of the samples was also
determined, using Hoechst 33258, and converted to mg
using a DNA standard curve, then the hydroxyproline
results were normalized according to the DNA content of
each sample.
2.9. Determination of glucosaminoglycan
(sGAG) deposition in the scaffold-free system
Determination of sGAG deposition as an indicator of the
ECM produced by the cells in culture was carried out us-
ing 1,9-dimethylmethylene blue (DMMB) assay (Müller
and Hanschke, 1996). Cells (25 000 cells/well) were in-
troduced to 1.5ml polypropylene tubes and the samples
were digested in 300 mg/ml papain in 20mM sodium
phosphate, pH 6.8, 1mM EDTA and 2mM dithiothreitol
at 60 C for 1 h. Digested samples (100 ml) were mixed
with 200 ml DMMB solution (16mg/l in glycine, NaCl
and HCl, pH 3.0) and the absorbance was measured at
525 nm in the microplate reader. The data were converted
to the amount of chondroitin sulphate, using a
Table 1. Medium contents of cell-seeded samples in a 24-
well plate
Sample PLGA nanocapsules PNIPAM nanospheres
OC – –
EP + Empty –
EN – + Empty
IP +IGF-I –
TN – + TGF-b1
IPTN +IGF-I + TGF-b1
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chondroitin sulphate standard curve. DNA content of the
samples were also determined using Hoechst 33258 and
converted to mg using the DNA standard curve, and then
the sGAG results were normalized according to the DNA
content of each sample.
2.10. Detection of collagen type II and aggrecan
deposited in the scaffold-free system
Detection of ECM produced by the BMSCs was made us-
ing immunohistochemistry. First, the samples described
in Section 2.6 were fixed in 3.7% formaldehyde solution
for 1 h. For collagen type II, samples were washed with
PBS and stored in 3% FBS/PBS for 10min. The solution
was removed and collagen type II mouse monoclonal
primer antibody IgG2b (Ab, 1.5% FBS/PBS 1:100; Santa
Cruz Biotechnology, Heidelberg,Germany) was added. Af-
ter incubation at room temperature for 6 h, the samples
were washed with PBS. Goat anti-mouse antibody IgG–
FITC (1% FBS/PBS 1:200; Santa Cruz Biotechnology)
was added as the secondary Ab after washing and then
the samples were incubated at 37 C for 45min. Unbound
antibody was removed by washing with PBS.
The other ECM component, aggrecan, was stained with
aggrecan rabbit polyclonal IgG Ab solution (1.5% FBS:PBS
1:200, Santa Cruz Biotechnology) after incubation in it for
6h at room temperature. The samples were washed with
PBS and secondary Ab solution, anti-rabbit AlexaFluorW
647 (1% FBS:PBS 1:200, Invitrogen) was added to each
sample and the samples were incubated at 37 C for
45min. After the incubation, the samples were washed with
PBS.
The stained samples were investigated using a confocal
microscopy (Leica TCS SP2 Laser Scanning Spectral Con-
focal System, Wetzlar, Germany).
2.11. Preparation and characterization of
PLGA scaffolds
PLGA (50:50) was dissolved in dichloromethane (0.08 g/
ml). NaCl crystals (300–500 mm) were introduced and air-
dried. The scaffolds were then dialysed against distilled
water, frozen at 20 C and lyophilized. The pore sizes
were determined using the SEM micrographs. Degrada-
tion of the foam was carried out for 60 days by immersing
the PLGA scaffolds in PBS (pH 7.4, 0.1M, room tempera-
ture; data not shown).
2.12. Cell proliferation on PLGA scaffolds
PLGA scaffolds (7mm diameter 1.9mm thickness) were
placed in 24-well plates and 250ml chondroitin sulphate
(CS; 1% sodium salt from bovine trachea, ca. 70%, Sigma-
Aldrich) was added to each scaffold (except the control)
and then forced into the pores of the scaffold by the applica-
tion of vacuum–pressure cycles with 30 s intermissions.
Different combinations of nanoparticles (PLGA, PNIPAM
or both, growth factor-loaded or -free) were added to the
PLGA–CS scaffolds according to Table 2 and a vacuum–
pressure cycle was applied to insert the particles into the
scaffolds. Each scaffold was seeded with 25 000 cells and
the samples were incubated for 2 h in a CO2 incubator
(37 C, 5% CO2). After cell seeding, alginic acid (500ml,
2%; Sigma-Aldrich) was introduced to the scaffolds to en-
trap the nanoparticles under a coat of alginic acid inside
the 3D matrix, which was crosslinked with Ca+2.
The scaffolds carrying chondroitin sulphate and algi-
nate (CSA) were washed with PBS and 1ml cartilage dif-
ferentiation medium was added into each well. CSA was
the control for both EP and EN. The plates were incubated
under 5% CO2 at 37 C. Cell numbers were determined as
described in the scaffold-free system.
2.13. Analysis of the total RNA with real-time PCR
Total RNA was isolated from the wells on days 1, 7
and 14 of incubation, using an RNeasy Mini Kit
(Qiagen, Düsseldorf, Germany). First-strand cDNA
synthesis was performed using Sensiscript Reverse
Transcriptase. Sequences used for real-time PCR were;
b-actin, forward 5′-TTCTACAATGAGCTGCGTGTG-3′,
reverse 5′-GCTGGGGTGTTGAAGGTC-3′ (125bp); collagen
type II, forward 5′-TGAACAACCAGATCGAGAGCA-3′, reverse
5′-CCAGTCTCCATGTTGCAGAAG-3′ (175bp); aggrecan,
forward 5′-TTGTGACTCTGCGGGTCATC-3′, reverse 5′-
GTCCCTAGGAGGGCCTTCAG-3′ (112bp). Aggrecan primer
sequences were taken from a study by Zheng et al. (2007)
and the other primers were designed in our laboratory. All
the primers were purchased from Invitrogen.
For each sample, 12.5 ml Maxima SYBR Green qPCR
Master Mix (2; Fermentas, Vilnius, Lithuania), 0.5 ml
forward and reverse primer for each (from 10mM), a 2 ml
template and 9 ml distilled water were used in an iCycler™
real-time system (Bio-Rad, CA, USA). The range of
relative gene dosage of aggrecan and collagen type II
was determined from 2–ΔΔCt.
2.14. Detection of sGAG produced on PLGA
scaffolds
sGAG production by the cells in the matrix were studied
using an Alcian blue staining kit (Bio-Optica, Italy). PLGA








OC – – – –
CSA + – – +
EP + + Empty – +
EN + – + Empty +
IP + + IGF-l – +
TN + – +TGF-b1 +
IPTN + + IGF-l +TGF-b1 +
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scaffolds were washed with distilled water and 10 drops
of reagent A of the kit were added and incubated for
30min. The solution was drained and 10 drops of reagent
B were added. After 10min the samples were washed
with distilled water and 10 drops of reagent C were
added. The final washing step with distilled water was
followed by an examination under a light microscope
(Nikon, Tokyo, Japan) and scored by at least two investi-
gators according the matrix staining (Alcian blue stain)
histological grading scale; no stain, 0; faint staining, 1; re-
duced staining, 2; normal staining, 3.
2.15. Statistical analysis
Statistical significance was assessed using the Mann–
Whitney non-parametric U-test. Significant difference
was statistically considered at the level of p≤ 0.05. Data
analyses were performed using SPSS 19.0.
3. Results and discussion
In this study, two growth factors, IGF-I and TGF-b1, were
entrapped in synthetic polymeric nanoparticles of PLGA
and PNIPAM and were tested either as such or after load-
ing into macroporous PLGA scaffolds to study their effect
on tissue-engineered cartilage production through BMSC
proliferation and differentiation into chondrocytes.
3.1. Nanoparticle properties
3.1.1. Nanoparticle size and distribution
PLGA nanocapsules were observed to have smooth sur-
faces (Figure 1a), with an average diameter of
32742nm and a particle size range of 190–615nm.
Their wall thicknesses were measured from the SEMs to
be ca. 50–70 nm.
The average particle size of PNIPAM nanospheres
was 22517nm and they had a particle size range of
205–256 nm (Figure 1b). They were also spherical but ag-
gregation of the particles due to the drying process in
SEM preparations was observed in the micrographs.
3.1.2. Encapsulation efficiency and loading
In order to determine the encapsulation efficiency, load-
ing and release kinetics, BSA was used in place of the
growth factors because this allowed us to use larger
amounts in quantification and thus have higher accuracy
in the detection of the protein than that of growth factors.
The encapsulation efficiency (amount loaded/initial
amount) of PLGA nanocapsules was 84.75% and the load-
ing was 0.67 mg/mg. For TGF-b1-loaded PNIPAM nano-
particles, the encapsulation efficiency and loading were
13.97% and 0.014 mg/mg, respectively.
3.1.2. BSA release from the nanoparticles
The release of BSA from PLGA and PNIPAM nanoparticles
could be better represented with Higuchi kinetics. It was
observed with the same PLGA nanocapsules that their re-
lease behaviour fitted the Higuchi model, with a k value of
0.0908 (Yilgor et al., 2009). For PNIPAM nanospheres, the
Higuchi kinetic constant k was 0.155, indicating a faster
release than from PLGA.
3.2. Influence of growth factor release under
in vitro conditions on TCPS
3.2.1. Cell proliferation
The influence of simultaneous release of two growth fac-
tors from the nanoparticles (IPTN) was compared with
those from nanoparticles with single growth factor (IP
or TN).
The cell numbers on day 1 were generally regarded as
an indicator of the level of cell adhesion on a carrier. Sam-
ples were seeded with cells (10 000 cells/well) and on
day 1 they all had approximately the same number of cells
(10 000–20 000 cells/well), with no indication of an influ-
ence of growth factors or the nanoparticles (Figure 2).
Figure 1. SEM micrographs of nanoparticles: (a) PLGA nanocapsules; (b) PNIPAM nanospheres (magnification50 000)
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The trends changed on the following days. Cell numb-
ers on empty or IGF-I-loaded nanoparticles (OC, EP, EN
and IP) reached a maximum on day 7, but all decreased
towards day 14, possibly due to overgrowth, contact inhi-
bition and detachment of the cells. The numbers were
very close.
On the other hand, TGF-b1 loaded alone or with IGF-I
(TN and IPTN) led to steady increase in the cell numbers
throughout the 14days of incubation. TGF-b1 is known to
have an indirect mitogenic effect for stromal MSCs and is
a stimulator of ECM deposition (Moses et al., 1991; Kay
et al., 1998; Lee et al., 2006). This suggests that TGF-b1
in the medium encourages differentiation in both TN and
IPTN samples, which may lead to slower cell growth than
the others and does not become inhibited by overgrowth.
A statistically significant difference between IPTN and IP
was observed on day 14.
3.2.2. Total collagen formation
This assay was carried out to determine the amount of col-
lagen secreted by the cells under the influence of the var-
ious combinations of the growth factors. After 1 day of
incubation, all the samples except IP showed very low col-
lagen production. The highest collagen formation was
observed on day 7 for all samples throughout 14 days of
incubation, except for IP (Figure 3). Some increase in col-
lagen formation in the TN-containing samples and in the
control (OC) was also detectable. Collagen formation on
IP was higher than the others at day 7 and continued to
increase until day 14. On the other hand, collagen produc-
tion decreased substantially in all samples except IP by
day 14.
The collagen production levels of both growth factor-
carrying samples were significantly higher than their GF-
free controls but lower than IP (single growth factor
IGF-I). This was expected, because IGF-I is known to stim-
ulate collagen production (Sonal, 2001; Olesen et al.,
2007). Worster et al. (2001) also found that collagen type
II deposition was evident in IGF-I-treated mesenchymal
stem cell progenitor cultures.
3.2.3. sGAG determination
The sGAG production by bone marrow stem cells’ growth
in medium supplemented with different growth factors
was determined by DMMB assay. On day 1, all samples ex-
cept the control showed some degree of sGAG formation
(Figure 4). After 7 days in culture, there was an increased
sGAG formation by cells in OC-, EN-, IP- and IPTN-treated
Figure 2. Cell growth determination using different growth factor combinations in the culture medium at the end of 1, 7 and 14days
of incubation, by MTS assay. Initial cell number was 10 000 cells/well. Statistical analysis was carried out for the comparison of IP and
TN with EP and EN, respectively, and IPTN with IP and TN. OC, only cell; EP, empty PLGA; EN, empty PNIPAM; IP, IGF-I in PLGA; TN,
TGF–b1 in PNIPAM; IPTN, IGF-I in PLGA and TGF–b1 in PNIPAM. *Statistically significant difference between IP and IPTN. Statistically
significant differences are labelled for p<0.05 level (n=3)
Figure 3. Total collagen production by cells in the presence of different growth factors at the end of 1, 7 and 14days of culture, by
hydroxyproline assay. Statistical analysis was carried out for the comparison of IP and TN with EP and EN, respectively, and for the
comparison of IPTN with IP and TN. OC, only cell; EP, empty PLGA; EN, empty PNIPAM; IP, IGF-I in PLGA; TN, TGF–b1 in PNIPAM;
IPTN, IGF-I in PLGA and TGF-b1 in PNIPAM. Statistical analysis was carried out for the comparison of EP–IP, EN–TN, IP–IPTN and
TN–IPTN, which are denoted **, †, * and #, respectively. Significant differences are labelled for p<0.05 level (n=3)
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samples. In the following week (14 days), however, the
sGAG production level was substantially improved in sam-
ples EN, TN and IPTN, with TN showing the highest value.
IGF-I- or TGF-b1-added samples showed statistically sig-
nificant higher sGAG production than their GF-free controls.
The highest levels of sGAG formation were observed in
TGF-b1-carrying TN and IPTN samples. There have been
several publications reporting a similar effect of TGF-b1
on aggrecan deposition (Kudo et al., 2001; Yamanishi
et al., 2002). Worster et al. (2001) found that medium
GAG content in MSC and chondrocyte monolayer cultures
was significantly (1.9–3.3-fold) increased above controls
by TGF-b1 treatment in 6 day cultures.
In the present study, the empty nanoparticles showed
the same behaviour on differentiation as in the case of hy-
droxyproline assay. The presence of sGAG in the absence
of growth factors in the OC samples was probably due to
incubation in the cartilage differentiation medium.
3.2.4. Confocal microscopy for collagen type II
and aggrecan
ECM deposition by BMSC was determined by confocal mi-
croscopy of samples double-stained for both collagen type
II and aggrecan. Articular cartilage isolated from rat knee
joint was used as the positive control. On day 7, IP, TN and
IPTN exhibited more collagen type II and aggrecan depo-
sition than the only cell control, OC (Figure 5b–e). On day
14, collagen type II and aggrecan secreted by OC, IP, TN
and IPTN were higher (Figure 5f–i), whereas TN and
IPTN had still higher deposition than OC.
It was observed that collagen type II was deposited
around the nucleus in the positive control, which was
rat articular cartilage (Figure 5a). The negative control
(OC) (Figure 5b, c) showed high collagen type II expres-
sion, as was also found in the hydroxyproline assay
(Figure 3), but the collagen deposition around the nu-
cleus was not the same as it was in the positive control
(Figure 5a). On the other hand, TN and IPTN showed sim-
ilar accumulation patterns of collagen type II around the
nucleus with articular cartilage cells. Moreover, TN
showed high amounts of aggrecan deposition, which sup-
ports the data of the DMMB assay. Johnstone et al. (1998)
reported the stimulation of cartilage-specific proteoglycan
production by TGF-b1. Connelly et al. (2008) also
reported the promotion of aggrecan gene expression and
sGAG accumulation of BMSCs by TGF-b1.
3.3. In vitro studies of cells on scaffolds
3.3.1. Properties of the PLGA scaffolds
The scaffolds were made with PLGA, chondroitin sulphate
and alginic acid, with the main frame being PLGA. The po-
rosity and degradation rate of PLGA scaffolds were studied
before starting the cell-seeding experiments. The pore size
and distribution are quite important parameters for cell
growth inside the scaffolds. The pores of the PLGA scaffold
were evenly distributed and their sizes were in the range
200–400mm, large enough for cell penetration and growth.
An in situ degradation study performed on a cell-free scaf-
fold in PBS at pH 7.4 showed that at the end of 40days of
incubation,> 90% (by weight) of the PLGA foams were de-
graded (data not shown). Degradation was accompanied
by a pH decrease to 2.6, probably due to the release of lac-
tic acid, glycolic acid and their oligomers.
Chondroitin sulphate introduced into the scaffold is
also an essential component of natural cartilage tissue.
According to Hardingham (1998), its presence in the scaf-
fold might lead to differentiation. Thus CS could help the
differentiation of MSCs into chondrocytes. The final com-
ponent, alginic acid, was chosen because of its biocompat-
ibility. Thus, the three-component system, with its
degradability, biocompatibility and large pores, was an
appropriate carrier for MSCs.
3.3.2. Cell proliferation on PLGA scaffolds
The cell number on day 1 was lower in all the samples
than the initial cell-seeding density (25 000 cells/well),
indicating that not all cells had adhered (Figure 6). There
was no significant increase in cell numbers in the control
OC throughout the 14days of incubation, probably due
to the medium being a cartilage differentiation medium.
The amount of cells on CSA and IP increased throughout
7 days of incubation and then decreased towards day 14.
Figure 4. sGAG formation by cells in the presence of different growth factors at the end of 1, 7 and 14days, by DMMB assay. Statistical
analysis was carried out for the comparison of IP and TN with EP and EN, respectively, and IPTN with IP and TN. OC, only cell; EP,
empty PLGA; EN, empty PNIPAM; IP, IGF-I in PLGA; TN, TGF–b1 in PNIPAM; IPTN, IGF-I in PLGA and TGF–b1 in PNIPAM. Significant
differences are labelled for p<0.05 level (n=3). #, **, † and * indicate statistically significant differences between EP–IP, EN–TN,
IP–IPTN and TN–IPTN, respectively
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A similar trend was observed in cell proliferation on TCPS.
However, TN and IPTN showed a continuous decrease
through days 7 and 14. This observation is not in agree-
ment with the results on TCPS (Figure 2), where both
TN and IPTN had shown continuous increase throughout
the 14day incubation. A reason for this decrease could
be the effect of chondroitin sulphate (CS), which was
not included in the OC and TCPS samples, where no car-
rier, and therefore no CS, was used. CS in known to en-
courage the differentiation of cells and differentiation is
known to decrease proliferation. It was reported that the
addition of chondroitin sulphate (CS) in to a polyethylene
glycol (PEG)-based hydrogel increased chondrogenic dif-
ferentiation of goat MSCs (Choi et al., 2010). Sechriest
et al. (2000) also showed that CS in the scaffold promoted
the secretion of proteoglycan and type II collagen, both of
which are indicators of differentiation.
3.3.3. Collagen type II and aggrecan expression
Real-time PCR was used to investigate the expression
levels of cartilage differentiation markers, such as
Figure 5. ECM deposition by cells grown in different culture media. Collagen type II (green) and aggrecan (red) double staining: (a)
rat knee joint articular cartilage; (b, d, f, h) OC, IP, TN, IPTN at the end of 7days of incubation; (c, e, g, i) OC, IP, TN, IPTN at the end of
14days of incubation (magnification63)
Figure 6. Cell growth determination in different culture media at the end of 1, 7 and 14days of incubation on PLGA scaffolds, by MTS
assay. OC samples do not contain CSA. Initial cell number was 25 000 cells/well. OC, only cell; CSA, chondroitin sulphate and alginate
added control; EP, empty PLGA; EN, empty PNIPAM; IP, IGF-I in PLGA; TN, TGF–b1 in PNIPAM; IPTN, IGF-I in PLGA and TGF–b1 in
PNIPAM. *Statistical significance difference between TN and IPTN. Significant differences are labelled for p<0.05 level (n=3)
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collagen type II and aggrecan. IPTN exhibited the most
collagen type II expression at all time points (Figure 7a);
especially after 14 days, collagen type II expression of
IPTN increased significantly.
For aggrecan, real-time PCR showed that higher aggre-
can expressions were observed on days 1 and 14
(Figure 7b); especially IPTN had significantly higher ex-
pression levels at the end of 14 days. Thus, IPTN led to
the highest expression of both collagen and aggrecan.
Collagen type II is the major component of hyaline car-
tilage (Pulkkinen et al., 2008) and aggrecan is a major
proteoglycan in the articular cartilage, providing the
scaffold with a hydrated gel structure that enables the
cartilage to carry loads (Kiani et al., 2002). The highest
collagen type II and aggrecan expressions were in IPTN
samples. In the samples tested on TCPS, the IP had pro-
duced the largest amount of total collagen and TN pro-
duced the highest sGAG. However, when the 3D PLGA
scaffolds were used, the IPTN group had the highest
amount of both the collagen type II and aggrecan gene ex-
pression. Since the IPTN sample had both IP and TN, their
synergic effect had apparently made a positive impact on
differentiation of the stem cells.
In principle, the activities of chondrocytes are observed
when they are placed in a proper 3D environment. During
the development and growth of cartilage, the chondro-
cytes produce abundant ECM (mainly collagen type II
and sGAG), encase themselves and are eventually sepa-
rated from each other (Yamaoka et al., 2006). 3D scaf-
folds provide a suitable environment for such activities:
they also allow for controlled local delivery of bioactive
agents, such as polypeptides or chemical molecules, that
stimulate cartilage-like tissue formation (Kuo et al.,
2006). These are all absent in a 2D cell carrier, which is
the scaffold-free TCPS system in this study.
3D scaffolds have some specific advantages, such as po-
rosity for cell attachment and migration inside of the mate-
rial. They provide a 3D framework to support the tissue or
Figure 7. Real-time PCR results for samples on the matrix for three time points: (a) collagen type II; (b) aggrecan marker proteins.
OC, only cell; CSA, chondroitin sulphate and alginate added control; EP, empty PLGA; EN, empty PNIPAM; IP, IGF-I in PLGA; TN,
TGF–b1 in PNIPAM; IPTN, IGF-I in PLGA and TGF–b1 in PNIPAM. Statistical analysis was carried out for the comparison of EP–IP,
EN–TN, IP–IPTN and TN–IPTN, which are denoted (a) †, **, {, # and *; (b) #, †, * and **, respectively. Significant differences are
labelled for p<0.05 level (n=3)
Figure 8. sGAG formation of IPTN samples in the PLGA scaffolds, as shown by Alcian blue (stains chondroitin sulphate blue) and nu-
clear fast red (stains the nucleus red) staining at the end of: (a) 1 day; (b) 14days of incubation (magnification4)
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cells. The scaffold not only provides mechanical support but
must also supply critical nutrients and transport metabolites
to and from the developing tissue (Fauci et al. 2008). Impor-
tant scaffold properties vary, depending on the tissue, but
typically include specific biomechanical properties, porosity,
biocompatibility and appropriate surface characteristics for
cell adhesion and differentiation.
3.3.4. sGAG localization in the cells
sGAG in the cells was studied using light microscopy. The
cell body was stained blue with Alcian blue and the nu-
cleus was stained red with nuclear fast red. On day 1, only
the nuclei of all the samples were stained red, which
meant that neither of the samples produced sGAG. After
7 days in culture there was sGAG production in all the
samples. Figure 8 shows Alcian blue-stained cells on IPTN.
Also, the highest sGAG content was observed on IP and
IPTN samples (Figure 9).
4. Conclusion
In this study, the influence of growth factors IGF-I and
TGF-b1 released from biodegradable nanoparticles was
studied on TCPS and on PLGA scaffolds carrying these
nanoparticles. It was seen that samples carrying both
nanoparticles led to the best results with respect to carti-
lage differentiation results on the scaffolds. It thus
appears that use of growth factor-loaded nanoparticles
could have a significant contribution for cartilage tissue
engineering.
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